Harnessing host innate immunity may combat acquired resistance to BRAFi
© Tan et al; licensee BioMed Central Ltd. 2014
Published: 6 May 2014
Natural Killer (NK) cells are innate immunity lymphocytes that spontaneously recognise and kill melanoma cells . Dacarbazine synergises with host immunity by inducing stress signals (NKG2D-L) that alert NK cells.This provides an example of how cancer therapies and host innate immunity may be combined to improve management of melanoma patients. BRAF inhibitors (BRAFi) are radically changing clinical practice in melanoma treatment because they offer unprecedented survival gains. However, melanoma patients nearly always relapse with drug-resistant disease after 6-12 months into the treatment. While evidence is emerging that BRAFi may modulate host immunity, the effect of BRAFi on the cross talk between NK cells and melanoma cells is unknown.
Material and methods
BRAF-mutant melanoma cell lines 1520, SK-MEL-37 and Colo38 were cultured for 4 weeks in the presence of 5μM vemurafenib. BRAFi-resistant variants were sequenced to confirm the presence of the BRAFV600E mutation and exclude outgrowth of BRAFWT clones. NK cells were isolated from the blood of healthy donors and activated with IL-2. Melanoma cell killing by NK cells was quantified before and after BRAFi treatment by FACS (CD107 degranulation assay) and/or by chromium release assays. MAPK signalling in melanoma cells was quantified by FACS (phospho-ERK). Expression of HLA class I, TRAIL, PD-1L as well as ligands for NKG2D, NCRs and DNAM-1 on melanoma cells was assessed by FACS. Receptor expression was assessed by FACS on blood NK cells from healthy donors or by confocal microscopy in lymph node biopsies of metastatic melanoma patients.
Melanoma cells that acquired BRAFi resistance through increased MAPK signalling developed also resistance towards NK cell killing. Expression of HLA class I, PD-1L and TRAIL was often elevated in drug-resistant melanoma cells compared to parental melanoma cells, whereas the expression of other NK receptor ligands did not significantly change. PD-1 was found on a subset of NK cells from some melanoma patients and on IL-2 activated NK cells from some healthy donors.
These data suggest that the PD-1/PD-L1 pathway is an attractive target to restore NK cell activity towards melanoma cells in some patients, thus harnessing host innate immunity to combat acquired BRAFi-resistance.
- Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni M, Umansky V, Paschen A, Sucker A, Pende D, Groh V, Biassoni R, Höglund P, Kato M, Shibuya K, Schadendorf D, Anichini A, Ferrone S, Velardi A, Kärre K, Shibuya A, Carbone E, Colucci F: NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest. 2009, 119 (5): 1251-63. 10.1172/JCI36022.PubMed CentralView ArticlePubMedGoogle Scholar
- Hervieu A, Rébé C, Végran F, Chalmin F, Bruchard M, Vabres P, Apetoh L, Ghiringhelli F, Mignot G: Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J Invest Dermatol. 2013, 133 (2): 499-508. 10.1038/jid.2012.273.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.